Targets › DNASE1
7 programs from 7 companies in 7 trials: 3 Phase 2, 2 Phase 4, 1 Phase 1, 1 Phase 3; Infectious disease, Neurology, Oncology; next expected readout Jul 2027.
Serum endocuclease secreted into body fluids by a wide variety of exocrine and endocrine organs. Expressed by non-hematopoietic tissues and preferentially cleaves protein-free DNA (By similarity). (UniProt, P24855)
Open in Phaseline: the race on DNASE1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of North Carolina, Chapel Hill | Deoxyribonuclease (DNase) DNA degradation enzyme; degrades extracellular DNA in biofilms to reduce viscosity | DNASE1 | Phase 4 | Pleural Infection Bacterial | Sep 2028 |
| Amsterdam UMC | DNase Deoxyribonuclease - breaks down extracellular DNA in biofilms | DNASE1 | Phase 4 | Empyema, Pleural | Oct 2028 |
| University Hospital, Strasbourg, France | Dornase Alfa Inhalant Solution [Pulmozyme] Recombinant deoxyribonuclease (DNase) that degrades nucleic acids in DAMPs and neutrophil | DNASE1 | Phase 3 | Multiple Trauma | Sep 2027 |
| National Cancer Institute, Slovakia | dornase alfa recombinant human DNase I that degrades extracellular DNA and restores DNA homeostasis | DNASE1 | Phase 2 | Refractory Germ Cell Tumors | Jul 2027 |
| Ludwig-Maximilians - University of Munich | Dornase Alfa DNase 1 (deoxyribonuclease 1) - endonuclease that cleaves extracellular DNA to reduce syst | DNASE1 | Phase 2 | Ischemic Stroke | Mar 2028 |
| Jon Simmons | Pulmozyme / Recombinant human deoxyribonuclease (rh-DNase) Recombinant human DNase that cleaves extracellular DNA, reducing mucus viscosity and airwa | DNASE1 | Phase 2 | Covid19 | – |
| McMaster University | Intravenous DNase I DNase I enzyme; cleaves extracellular DNA in neutrophil extracellular traps (NETs) | DNASE1 | Phase 1 | Sepsis | – |
Pleural Infection Bacterial (1) Sepsis (1) Empyema, Pleural (1) Ischemic Stroke (1) Covid19 (1) Refractory Germ Cell Tumors (1) Multiple Trauma (1)
mixed (4), protein or peptide (2), small molecule (1)
University of North Carolina, Chapel Hill (1) McMaster University (1) Amsterdam UMC (1) Ludwig-Maximilians - University of Munich (1) Jon Simmons (1) National Cancer Institute, Slovakia (1) University Hospital, Strasbourg, France (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.